All Stories

  1. High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study

    Article • International Journal of Clinical Oncology, March 2025, Springer Science + Business Media

    Satoshi Ikeda

  2. Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study

    Article • Respiratory Investigation, January 2025, Elsevier

    Satoshi Ikeda

  3. Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database

    Article • Lung Cancer, January 2025, Elsevier

    Satoshi Ikeda

  4. Patient‐Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non‐Small Cell Lung Cancer in Japan

    Article • Cancer Medicine, November 2024, Wiley

    Satoshi Ikeda

  5. Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease

    Article • Journal of Infection and Chemotherapy, September 2024, Elsevier

    Satoshi Ikeda

  6. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)

    Article • Lung Cancer, August 2024, Elsevier

    Satoshi Ikeda

  7. Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study

    Article • Respiratory Investigation, May 2024, Elsevier

    Satoshi Ikeda

  8. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis

    Article • Cancers, April 2024, MDPI AG

    Satoshi Ikeda

  9. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

    Article • Targeted Oncology, April 2024, Springer Science + Business Media

    Satoshi Ikeda

  10. KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

    Article • Cancers, March 2024, MDPI AG

    Satoshi Ikeda

  11. Phase 2 study of Nintedanib + Chemo for SCLC with IPF

    Article • Annals of the American Thoracic Society, February 2024, American Thoracic Society

    Satoshi Ikeda

  12. Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia

    Article • Cancers, January 2024, MDPI AG

    Satoshi Ikeda

  13. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)

    Article • Clinical Cancer Research, January 2024, American Association for Cancer Research (AACR)

    Satoshi Ikeda

  14. Trapped Lung as a Sequela of Dramatic Tumor Shrinkage of Lung Cancer

    Article • Internal Medicine, January 2024, Japanese Society of Internal Medicine

    Satoshi Ikeda

  15. Hypersensitivity pneumonitis with Paecilomyces as suspected inciting antigen

    Article • Respiratory Medicine Case Reports, January 2024, Elsevier

    Satoshi Ikeda

  16. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma

    Article • JTO Clinical and Research Reports, January 2024, Elsevier

    Satoshi Ikeda

  17. A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib

    Article • Scientific Reports, December 2023, Springer Science + Business Media

    Satoshi Ikeda

  18. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer

    Article • JAMA Network Open, December 2023, American Medical Association (AMA)

    Satoshi Ikeda

  19. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)

    Article • JTO Clinical and Research Reports, December 2023, Elsevier

    Satoshi Ikeda

  20. High prevalence of upper lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis in patients with round atelectasis

    Article • Respiratory Investigation, November 2023, Elsevier

    Satoshi Ikeda

  21. Notch1 and CREBBP Co-Mutations Affect Adjuvant Therapy Benefit in EGFR-Mutated NSCLC

    Article • Molecular Oncology, October 2023, Wiley

    Satoshi Ikeda

  22. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

    Article • International Journal of Clinical Oncology, September 2023, Springer Science + Business Media

    Satoshi Ikeda

  23. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

    Article • International Journal of Clinical Oncology, August 2023, Springer Science + Business Media

    Satoshi Ikeda

  24. Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.

    Article • Journal of Clinical Oncology, June 2023, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  25. Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.

    Article • Journal of Clinical Oncology, June 2023, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  26. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial

    Article • Clinical Lung Cancer, June 2023, Elsevier

    Satoshi Ikeda

  27. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report

    Article • Molecular and Clinical Oncology, May 2023, Spandidos Publications

    Satoshi Ikeda

  28. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)

    Article • Clinical Lung Cancer, May 2023, Elsevier

    Satoshi Ikeda

  29. Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke inBRAFV600E-mutant Non-small-cell Lung Cancer

    Article • Anticancer Research, January 2023, International Institute of Anticancer Research

    Satoshi Ikeda

  30. Prognosis of IPF patients with comorbid lung cancer: Preventing immortal time bias will make the analysis more valuable

    Article • Respirology, December 2022, Wiley

    Satoshi Ikeda

  31. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

    Article • Cancers, October 2022, MDPI AG

    Satoshi Ikeda, MD. PhD. Tateaki Naito

  32. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors be a Game Changer?

    Article • September 2022, MDPI AG

    Satoshi Ikeda, MD. PhD. Tateaki Naito

  33. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort

    Article • Annals of Oncology, September 2022, Elsevier

    Satoshi Ikeda

  34. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

    Article • Journal of Clinical Oncology, August 2022, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  35. Pharmacotherapy for Lung Cancer with Comorbid Interstitial Pneumonia: Limited Evidence requires Appropriate Evaluation

    Article • ERJ Open Research, August 2022, European Respiratory Society (ERS)

    Satoshi Ikeda

  36. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy

    Article • Thoracic Cancer, July 2022, Wiley

    Satoshi Ikeda

  37. Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases

    Article • CHEST Journal, July 2022, Elsevier

    Satoshi Ikeda

  38. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study

    Article • The Oncologist, June 2022, Oxford University Press (OUP)

    Satoshi Ikeda

  39. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration

    Article • Medicine, June 2022, Wolters Kluwer Health

    Satoshi Ikeda

  40. Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L)

    Article • Lung Cancer, April 2022, Elsevier

    Satoshi Ikeda

  41. Nintedanib plus chemotherapy for non–small cell lung cancer with IPF: a randomized phase 3 trial

    Article • European Respiratory Journal, March 2022, European Respiratory Society (ERS)

    Satoshi Ikeda

  42. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

    Article • International Journal of Clinical Oncology, February 2022, Springer Science + Business Media

    Satoshi Ikeda

  43. Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective

    Article • Radiotherapy and Oncology, February 2022, Elsevier

    Satoshi Ikeda

  44. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

    Article • JTO Clinical and Research Reports, February 2022, Elsevier

    Satoshi Ikeda

  45. Letter comments on anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study

    Article • European Journal of Cancer, February 2022, Elsevier

    Satoshi Ikeda

  46. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non–Small-Cell Lung Cancer (NSCLC)

    Article • JTO Clinical and Research Reports, February 2022, Elsevier

    Satoshi Ikeda

  47. Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection

    Article • Open Forum Infectious Diseases, December 2021, Oxford University Press (OUP)

    Satoshi Ikeda

  48. Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

    Article • Cancer Science, November 2021, Wiley

    Satoshi Ikeda

  49. Persistence of robust humoral immune response in COVID-19 convalescent individuals over 12 months after infection

    Article • September 2021, Cold Spring Harbor Laboratory Press

    Satoshi Ikeda

  50. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019

    Article • Respiratory Investigation, September 2021, Elsevier

    Satoshi Ikeda

  51. 1285P Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia

    Article • Annals of Oncology, September 2021, Elsevier

    Satoshi Ikeda

  52. Current Treatment Strategies for NSCLC with Comorbid IP

    Article • Cancers, August 2021, MDPI AG

    Satoshi Ikeda

  53. Impact of interstitial pneumonia complications on palliative medication for terminal lung cancer: A single-center retrospective study

    Article • Respiratory Investigation, August 2021, Elsevier

    Satoshi Ikeda

  54. MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L

    Article • Annals of Oncology, July 2021, Elsevier

    Satoshi Ikeda

  55. MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker

    Article • Annals of Oncology, July 2021, Elsevier

    Satoshi Ikeda

  56. Clinical characteristics of Japanese patients with moderate to severe COVID-19

    Article • Journal of Infection and Chemotherapy, June 2021, Elsevier

    Satoshi Ikeda

  57. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

    Article • ESMO Open, June 2021, Elsevier

    Satoshi Ikeda

  58. Asbestos exposure and tuberculous pleurisy as developmental causes of progressive unilateral upper-lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis

    Article • Respiratory Investigation, June 2021, Elsevier

    Satoshi Ikeda

  59. Spontaneous regression following endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer patients

    Article • Respiratory Investigation, June 2021, Elsevier

    Satoshi Ikeda

  60. A spectrum of Thymic mucosa-associated lymphoid tissue lymphoma and Thymic amyloidosis in the patient with Auto immune disease: a case series

    Article • Mediastinum, June 2021, AME Publishing Company

    Satoshi Ikeda

  61. Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer

    Article • Palliative Medicine Reports, June 2021, Mary Ann Liebert Inc

    Satoshi Ikeda

  62. Corticosteroids for COVID-19 (DEFEAT COVID-19)

    Article • Scientific Reports, May 2021, Springer Science + Business Media

    Satoshi Ikeda

  63. Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  64. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors

    Article • Frontiers in Microbiology, May 2021, Frontiers

    Satoshi Ikeda

  65. ICI for NSCLC with comorbid IP; a prudent stance required

    Article • European Journal of Cancer, May 2021, Elsevier

    Satoshi Ikeda

  66. Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity

    Article • Respiratory Investigation, March 2021, Elsevier

    Satoshi Ikeda

  67. FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial)

    Article • Journal of Thoracic Oncology, March 2021, Elsevier

    Satoshi Ikeda

  68. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease

    Article • Respiratory Investigation, February 2021, Elsevier

    Satoshi Ikeda

  69. Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐ PD ‐1 antibody

    Article • Thoracic Cancer, January 2021, Wiley

    Satoshi Ikeda

  70. Identification and Characteristics of Co-isolation of Multiple Nontuberculous Mycobacteria

    Article • Internal Medicine, January 2021, Japanese Society of Internal Medicine

    Satoshi Ikeda

  71. Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report

    Article • Respiratory Medicine Case Reports, January 2021, Elsevier

    Satoshi Ikeda

  72. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: A multicenter, retrospective, propensity score–matched study

    Article • November 2020, Research Square

    Satoshi Ikeda

  73. Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors

    Article • Internal Medicine, November 2020, Japanese Society of Internal Medicine

    Satoshi Ikeda

  74. Unilateral upper lung-field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis after thoracic surgery: Clinical and radiological courses with autopsy findings

    Article • Respiratory Investigation, November 2020, Elsevier

    Satoshi Ikeda

  75. Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren’s syndrome in transbronchial lung cryobiopsy

    Article • BMC Pulmonary Medicine, October 2020, Springer Science + Business Media

    Satoshi Ikeda

  76. Ramucirumab or placebo plus erlotinib in EGFR ‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

    Article • Cancer Science, October 2020, Wiley

    Satoshi Ikeda

  77. Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren's syndrome in transbronchial lung cryobiopsy

    Article • September 2020, Research Square

    Satoshi Ikeda

  78. Destructive bronchiolitis: a characteristic pathological feature of interstitial lung disease preceding the onset of rheumatoid arthritis

    Article • September 2020, European Respiratory Society (ERS)

    Midori Sato, Satoshi Ikeda

  79. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis

    Article • Respiratory Investigation, September 2020, Elsevier

    Satoshi Ikeda

  80. 1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA

    Article • Annals of Oncology, September 2020, Elsevier

    Satoshi Ikeda

  81. Relationship of flow-volume curve pattern on pulmonary function test with clinical and radiological features in idiopathic pulmonary fibrosis

    Article • BMC Pulmonary Medicine, August 2020, Springer Science + Business Media

    Satoshi Ikeda

  82. Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322

    Article • Lung Cancer, August 2020, Elsevier

    Satoshi Ikeda

  83. Atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonias

    Article • Journal of Thoracic Oncology, August 2020, Elsevier

    Satoshi Ikeda

  84. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases

    Article • Respiratory Investigation, August 2020, Elsevier

    Satoshi Ikeda

  85. Importance of doctor‐initiated management of the balance between work and treatment for lung cancer patients: Results of a nationwide survey by the Japan Lung Cancer Society

    Article • Cancer Medicine, July 2020, Wiley

    Satoshi Ikeda

  86. Small‑cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report

    Article • Molecular and Clinical Oncology, June 2020, Spandidos Publications

    Satoshi Ikeda

  87. Miliary lung metastases from ROS1‑rearranged lung adenocarcinoma: A case report

    Article • Molecular and Clinical Oncology, May 2020, Spandidos Publications

    Satoshi Ikeda

  88. Treatment rationale and design of a phase III study of Afatinib or CHemotherapy In patients with non-smaLL-cell lung cancer harboring sensitizing uncommon Epidermal growth factor receptor mutationS (ACHILLES/TORG1834)

    Article • Clinical Lung Cancer, May 2020, Elsevier

    Satoshi Ikeda

  89. Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease

    Article • Respiratory Investigation, May 2020, Elsevier

    Satoshi Ikeda

  90. Anterior mediastinal amyloidosis mimics thymic carcinoma

    Article • JTO Clinical and Research Reports, April 2020, Elsevier

    Satoshi Ikeda

  91. A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Satoshi Ikeda

  92. Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Satoshi Ikeda

  93. Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma with Smoking History: A Single-Center Experience

    Article • International Archives of Allergy and Immunology, January 2020, Karger Publishers

    Satoshi Ikeda

  94. Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty

    Article • Respirology Case Reports, December 2019, Wiley

    Satoshi Ikeda

  95. Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)

    Article • Annals of Oncology, November 2019, Elsevier

    Satoshi Ikeda

  96. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    Article • The Lancet Oncology, October 2019, Elsevier

    Satoshi Ikeda

  97. EP1.01-45 Cisplatin Plus Gemcitabine Therapy Followed by Maintenance Gemcitabine for Advanced Squamous Cell Lung Cancer (KTORG1302)

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Satoshi Ikeda

  98. MA13.07 Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Satoshi Ikeda

  99. Safety and learning curve for Transbronchial Lung Cryobiopsy

    Article • September 2019, European Respiratory Society (ERS)

    Satoshi Ikeda

  100. Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema

    Article • September 2019, European Respiratory Society (ERS)

    Satoshi Ikeda

  101. Utility of inhalation challenge test using avian egg for hypersensitivity pneumonia

    Article • September 2019, European Respiratory Society (ERS)

    Satoshi Ikeda

  102. A pilot study of endobronchial ultrasound guided cryobiopsy using extra-large size guide sheath

    Article • September 2019, European Respiratory Society (ERS)

    Satoshi Ikeda

  103. Erdheim‐Chester disease progression from miliary pulmonary nodules to large tumours

    Article • Respirology Case Reports, August 2019, Wiley

    Satoshi Ikeda

  104. A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302

    Article • Oncology, August 2019, Karger Publishers

    Satoshi Ikeda

  105. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

    Article • Respiratory Investigation, August 2019, Elsevier

    Satoshi Ikeda

  106. A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  107. Randomized Phase 2 Study of Nintedanib with or Without Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Who Experienced a Clinically Meaningful Decline in Forced Vital Capacity During Prior Pirfenidone Administration

    Article • May 2019, American Thoracic Society

    Satoshi Ikeda

  108. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

    Article • BMC Pulmonary Medicine, April 2019, Springer Science + Business Media

    Satoshi Ikeda

  109. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia

    Article • Respiratory Investigation, April 2019, Elsevier

    Satoshi Ikeda

  110. Rapid effect of osimertinib re‑challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report

    Article • Molecular and Clinical Oncology, February 2019, Spandidos Publications

    Satoshi Ikeda

  111. Pulmonary Follicular Lymphoma Showing Diffuse Micronodules Mimicking Sarcoidosis

    Article • Internal Medicine, February 2019, Japanese Society of Internal Medicine

    Satoshi Ikeda

  112. Low starting-dosage of nintedanib for the reduction of early termination

    Article • Respiratory Investigation, February 2019, Elsevier

    Satoshi Ikeda

  113. Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case

    Article • Internal Medicine, January 2019, Japanese Society of Internal Medicine

    Satoshi Ikeda

  114. Anti-Ku antibody-positive desquamative interstitial pneumonia

    Article • Respiratory Medicine Case Reports, January 2019, Elsevier

    Satoshi Ikeda

  115. Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease

    Article • Respiratory Investigation, January 2019, Elsevier

    Satoshi Ikeda

  116. Miliary lung metastases from non‑small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report

    Article • Molecular and Clinical Oncology, October 2018, Spandidos Publications

    Satoshi Ikeda

  117. Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome

    Article • Journal of Thoracic Disease, October 2018, AME Publishing Company

    Satoshi Ikeda

  118. P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)

    Article • Journal of Thoracic Oncology, October 2018, Elsevier

    Satoshi Ikeda

  119. Cystic lesion in myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)- positive interstitial pneumonia: radiological and pathological anaylsis

    Article • September 2018, European Respiratory Society (ERS)

    Satoshi Ikeda

  120. The correlation between pathological findings of transbronchial lung cryobiopsy and high resolution CT morphology for diffuse parenchymal lung disease patients

    Article • September 2018, European Respiratory Society (ERS)

    Satoshi Ikeda

  121. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer

    Article • Cancer Science, June 2018, Wiley

    Satoshi Ikeda

  122. Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies

    Article • Respiration, May 2018, Karger Publishers

    Satoshi Ikeda

  123. Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case

    Article • Journal of Thoracic Disease, May 2018, AME Publishing Company

    Satoshi Ikeda

  124. Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia

    Article • Respirology, April 2018, Wiley

    Satoshi Ikeda

  125. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoraci...

    Article • BMC Cancer, March 2018, Springer Science + Business Media

    Satoshi Ikeda

  126. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?

    Article • BMC Pulmonary Medicine, January 2018, Springer Science + Business Media

    Satoshi Ikeda

  127. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non–Small-Cell Lung Cancer Patients With an EGFR Mutation

    Article • Clinical Lung Cancer, January 2018, Elsevier

    Satoshi Ikeda

  128. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

    Article • BMC Cancer, November 2017, Springer Science + Business Media

    Satoshi Ikeda

  129. PROGNOSTIC FACTORS AND DISEASE BEHAVIOUR OF FIBROTIC NONSPECIFIC INTERSTITIAL PNEUMONIA

    Article • Respirology, November 2017, Wiley

    Satoshi Ikeda

  130. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis

    Article • Scientific Reports, September 2017, Springer Science + Business Media

    Satoshi Ikeda

  131. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study

    Article • European Respiratory Journal, August 2017, European Respiratory Society (ERS)

    Dr Anoop M Nambiar, Dr Giovanni Ferrara, Dr Michael Perch, Satoshi Ikeda, Dr Tiago M Alfaro, MD Pilar Rivera Ortega

  132. Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation–positive non-small cell lung cancer.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Satoshi Ikeda

  133. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

    Article • Journal of Thoracic Disease, February 2017, AME Publishing Company

    Satoshi Ikeda

  134. Unilateral Upper Lung Field Pulmonary Fibrosis Radiologically Consistent with Pleuroparenchymal Fibroelastosis after Thoracotomy: A New Disease Entity Related to Thoracotomy

    Article • Respiration, January 2017, Karger Publishers

    Satoshi Ikeda

  135. A case of relapsed lung abscess caused by Eubacterium brachy infection following an initial diagnosis of pulmonary actinomycosis

    Article • Respiratory Medicine Case Reports, January 2017, Elsevier

    Satoshi Ikeda

  136. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience

    Article • Respiratory Investigation, January 2017, Elsevier

    Satoshi Ikeda

  137. A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome

    Article • Internal Medicine, January 2017, Japanese Society of Internal Medicine

    Satoshi Ikeda

  138. Desquamative Interstitial Pneumonia Complicated with IgG4-related Lung Disease

    Article • Internal Medicine, January 2017, Japanese Society of Internal Medicine

    Satoshi Ikeda

  139. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity

    Article • Internal Medicine, January 2017, Japanese Society of Internal Medicine

    Satoshi Ikeda

  140. P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Satoshi Ikeda

  141. Meaning of IgG4-positive plasma cells in interstitial pneumonia

    Article • Histopathology, September 2016, Wiley

    Satoshi Ikeda

  142. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis

    Article • PLOS One, August 2016, PLOS

    Satoshi Ikeda

  143. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015

    Article • BMC Cancer, May 2016, Springer Science + Business Media

    Satoshi Ikeda

  144. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

    Article • Cancer Chemotherapy and Pharmacology, April 2016, Springer Science + Business Media

    Satoshi Ikeda

  145. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

    Article • BMC Pulmonary Medicine, March 2016, Springer Science + Business Media

    Satoshi Ikeda

  146. Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis

    Article • Journal of Thoracic Oncology, February 2016, Elsevier

    Satoshi Ikeda

  147. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

    Article • BMC Pulmonary Medicine, December 2015, Springer Science + Business Media

    Satoshi Ikeda

  148. Clinical characteristics of pneumonia in bedridden patients receiving home care: A 3-year prospective observational study

    Article • Journal of Infection and Chemotherapy, August 2015, Elsevier

    Satoshi Ikeda

  149. Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study

    Article • BMC Pulmonary Medicine, July 2015, Springer Science + Business Media

    Satoshi Ikeda

  150. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

    Article • SpringerPlus, May 2015, Springer Science + Business Media

    Satoshi Ikeda

  151. Chronological Assessment of Airway Lesions in Relapsing Polychondritis by Positron Emission Tomography

    Article • Internal Medicine, January 2015, Japanese Society of Internal Medicine

    Satoshi Ikeda

  152. Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia

    Article • Internal Medicine, January 2015, Japanese Society of Internal Medicine

    Satoshi Ikeda

  153. Interstitial lung disease induced by alectinib (CH5424802/RO5424802)

    Article • Japanese Journal of Clinical Oncology, November 2014, Oxford University Press (OUP)

    Satoshi Ikeda

  154. Clinical characteristics of severe community-acquired pneumonia among younger patients: An analysis of 18 years at a community hospital

    Article • Journal of Infection and Chemotherapy, August 2014, Elsevier

    Satoshi Ikeda

  155. Diffuse Alveolar Hemorrhage as a Fatal Adverse Effect of Bevacizumab: An Autopsy Case

    Article • Japanese Journal of Clinical Oncology, March 2014, Oxford University Press (OUP)

    Satoshi Ikeda